Imfinzi and Imjudo (durvalumab and tremelimumab)

pCPA File Number: 22493

Negotiation Status:

Concluded with an LOI

Indication(s):

Unresectable hepatocellular carcinoma (uHCC) in adult patients who require systemic therapy, first-line treatment

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CDA-AMC Project Number:

PC0308-000

pCPA Engagement Letter Issued:

2023-12-08

Negotiation Process Concluded:

2024-02-28